POS0211

PREDICTORS OF PROGRESSION AND MORTALITY IN PATIENTS WITH PREVALENT RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE: A PROSPECTIVE COHORT STUDY

N. Mena-Vázquez¹, M. Rojas-Giménez², C. M. Romero-Barco³, S. Manrique Arijia¹, F. Espildora⁴, M. C. Aguilar-Hurtado⁵, R. Ortega Castro⁶, I. Añón Oñate⁷, L. Pérez Albaladejo⁸, F. Godoy-Navarrete¹, I. Ureña¹, M. Velloso Feijoo⁹, R. Redondo¹, F. G. Jiménez-Núñez¹, B. Panero Lamothe¹⁰, M. I. Padin-Martín⁵, A. Fernandez-Nebro¹. ¹Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga (HRUM), Reumatología, Málaga, Spain; ²Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), UGC de Reumatología, Hospital Universitario Reina Sofía de Córdoba, Reumatología, 14004, Spain; ³Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Clínico Universitario Virgen de la Victoria, Reumatología, Málaga, Spain; ⁴Hospital Regional Universitario de Málaga (HRUM), Neumología, Málaga, Spain; ⁵Hospital Regional Universitario de Málaga (HRUM), Radiología, Málaga, Spain; ⁶Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), UGC de Reumatología, Hospital Universitario Reina Sofía de Córdoba, Reumatología, Córdoba, Spain; ⁷Hospital Universitario de Jaén, Reumatología, Jaén, Spain; ⁸Hospital Universitario Virgen de las Nieves, Reumatología, Granada, Spain; ⁹Hospital Universitario Virgen de Valme, Reumatología, Málaga, Spain; ¹⁰Hospital Clínico Universitario Virgen de la Victoria, Reumatología, Málaga, Spain

Objectives: To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) and identify risk factors associated with disease progression and mortality in patients with rheumatoid arthritis associated with interstitial lung disease (RA-ILD).

Methods: We performed a multicenter, prospective, observational study of patients with RA-ILD receiving DMARDs between 2015 and 2020. The patients were assessed using high-resolution computed tomography and pulmonary function tests at baseline and at 60 months. The main outcome measure at 60 months was worsening of FVC >10% or DLCO >15% and radiological progression or death. We recorded demographic and clinical characteristics, lung function, and the incidence of adverse events. A Cox regression analysis was performed to identify factors associated with worsening of ILD.

Results: After 60 months, lung disease had stabilized in 66 patients (56.9%), improved in 9 (7.8%), and worsened in 23 (19.8%). Eighteen patients (15.5%) died, with a mean survival of 71.8 (1.9) months. Baseline characteristics of 116 with RA-ILD treated with DMARDs is in table 1. The Cox multivariate analysis revealed the independent predictors of worsening of RA-ILD to be usual interstitial pneumonia (HR, 2.6 [95%CI, 1.0-6.7]), forced vital capacity (%) (HR, 3.8 [95%CI, 1.5-6.7]), anticitrullinated protein antibody titers (HR, 2.8 [95%CI, 1.1-6.8]), smoking (HR, 2.5 [95%CI, 1.1-6.2]), and treatment with abatacept, tocilizumab, or rituximab (HR, 0.4 [95%CI, 0.2-0.8]). During follow-up, 79 patients (68%) experienced an adverse event, mostly infection (61%).

Conclusion: Lung function is stable in most patients with RA-ILD receiving treatment with DMARDs, although one third of patients die. Identifying factors of worsening in RA-ILD is important for clinical management.

Table 1. Baseline characteristics of 116 with RA-ILD treated with DMARDs

Variable	Total=116
Epidemiological characteristics	
Female sex, n (%)	63 (54.3)
Age, years, mean (SD)	68.3 (9.9)
Clinical and analytical characteristics	
Current smoker	
Nonsmoker, n (%)	57 (49.1)
Smoker, n (%)	23 (19.8)
Exsmoker, n (%)	36 (31.0)
Time since diagnosis of RA, months, median (p25-p75)	148.5 (71.5-217.8)
Diagnostic delay, months, median (p25-p75)	8.5 (4.9-16.8)
Time since diagnosis of ILD, months, median (p25-p75)	27.5 (9.8-60.0)
Positive rheumatoid factor (>10), n (%)	111 (95.7)
Positive ACPA titer (>20), n (%)	100 (86.2)
Erosive disease, n (%)	76 (65.5)
Treatment Synthetic DMARD	100 (86.2)
Methotrexate, n (%)	51 (44.0)
Leflunomide, n (%)	30 (25.9)
Sulfasalazine, n (%)	9 (7.8)
Hydroxychloroquine, n (%)	2 (1.8)
Biologic DMARD	50 (43.1)
Infliximab, n (%)	1 (0.9)
Etanercept, n (%)	6 (5.2)
Adalimumab, n (%)	3 (2.6)
Golimumab, n (%)	3 (2.6)
Certolizumab, n (%)	3 (2.6)
Tocilizumab, n (%)	6 (5.2)
Abatacept, n (%)	15 (12.9)
Rituximab, n (%)	13 (11.2)
Immunosuppressants	11 (9.5)
Mycophenolate, n (%)	7 (6.0)
Azathioprine, n (%)	4 (3.4)
Antifibrotic agents, nintedanib, n (%)	1 (0.9)
Baseline corticosteroids, n (%)	69 (60.0)
Dose of baseline corticosteroids, median (p25-p75)	5.0 (0.0-7.5)

Abbreviations. RA: rheumatoid arthritis; ILD: interstitial lung disease; ACPA: anticitrullinated protein antibody; DMARD: disease-modifying antirheumatic drug; SD: standard deviation.

Acknowledgements: Grant for Medical Researchers of the "Fundación Española de Reumatología" 2019. declare.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1090

POS0212

COMPARISON OF PATIENT CHARACTERISTICS AND TREATMENT PATTERNS ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

E. Vallejo-Yagüe¹, T. Burkard¹, B. Moeller², A. Finckh³, A. M. Burden¹. ¹ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Zurich, Switzerland; ²Inselspital, University Hospital of Bern, Rheumatology, Immunology and Allergy, Bern, Switzerland; ³University Hospitals Geneva, Division of Rheumatology, Geneva, Switzerland

Background: Higher prevalence of obesity has been observed in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) versus the general population, and abnormal body mass index has been associated with worse rheumatic markers.

Objectives: To describe PsA and RA patients in Switzerland, stratified by body mass index (BMI) category.

Methods: We performed a descriptive cohort study in PsA and RA patients registered in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) database. Two distinct cohorts were generated based on patient diagnosis (PsA or RA) and analysed separately but using similar approaches. In both cohorts, we included patients treated for the first time with biologics or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs), and considered the treatment start as index date. Patients without baseline BMI were excluded. Patients were stratified by BMI category at the start of biologic/tsDMARD treatment, defined as underweight (BMI<18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), and obese (BMI≥30). In the PsA cohort, underweight and normal weight groups were merged due to low numbers. The proportion of patients categorized as overweight or underweight were compared to national statistics from the Swiss Federal Statistical Office. Information on patient demographics (e.g., age, sex, BMI, life-habits), disease-specific characteristics (e.g., disease activity scores, health questionnaires, biomarkers), co-medications and comorbidities were summarized at the start of the first biologic/tsDMARD treatment. Patient characteristics across BMI categories were compared, using the normal weight category as reference group. Additionally, we summarized the frequency and reasons for recorded treatment stop/switch at ≤6 months, 6 to 12 months, and >12months from treatment start, and illustrated the prescription patterns for first and second biologic/tsDMARD treatment, stratifying by BMI.

Results: We identified 819 PsA [39.7% normal weight, 36.5% overweight, 23.8% obese] and 3217 RA patients [4.4% underweight, 46.8% normal weight, 31.8% overweight, 17.0% obese]. Figure 1 illustrates the prevalence of overweight and obesity in each cohort stratified by sex, compared to the national average. When comparing obese patients to those with normal weight, both PsA and RA obese patients had significantly higher C-reactive protein, worse disease activity score, lower quality of life (QoL) measures, and more frequent cardiovascular disease and diabetes. Among PsA patients, the overweight and obese had worse physician-assessed skin manifestation and patient-reported pain compared to the normal weight group. While in RA, the obese patients had higher erythrocyte sedimentation rate, smaller prevalence of seropositive patients, lower frequency of fractures/surgeries, and higher tender joint counts, but similar swollen joint counts, when compared to the normal weight group. Adalimumab and etanercept, were the most commonly prescribed drugs as first biologic/tsDMARD treatment in both PsA and RA cohorts and among every BMI category. Overall, 55% PsA and 56% RA patients had recorded treatment stop/switch. Among RA patients, significantly fewer obese patients reported treatment stop/switch at >12 months from treatment start, compared to the normal weight group. Adalimumab and etanercept were also the most commonly prescribed second biologic/tsDMARD treatment, but for the obese group among PsA patients (adalimumab, golimumab) and the obese group in the RA cohort (adalimumab, rituximab).

Conclusion: In this national wide study, we observed that the prevalence of obesity in RA and PsA was higher than that of the general Swiss population. Obese PsA/RA patients starting first biologic/tsDMARD treatment presented worse disease activity and poorer QoL than normal weight patients. Results suggest to take BMI into consideration when treating PsA and RA patients.

Ref. Reference: >15 years old Swiss population in 2017.
 Übergewicht und Adipositas - Schweizerische Gesundheitsbefragung 2017 - Korrigierte Version 25.09.2020 |
 Publikation. Bundesamt für Statistik 2020. Accessed January 21, 2021. Available at:
<https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheits/erhebungen/sgb.assetdetail.14147705.html>
 RA rheumatoid arthritis. Study data.
 PsA psoriatic arthritis. Study data.